Evidence map›Paper›PMID 26185258›Full record

ArticleStem cells translational medicine2015

A Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction.

Vladimir Holan, Peter Trosan, Cestmir Cejka, Eliska Javorkova, Alena Zajicova, Barbora Hermankova, Milada Chudickova, Jitka Cejkova

Open access · goldAbstract readComparative Study
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Concise Review: Bioengineering of Limbal Stem Cell Niche.Bioengineering (Basel, Switzerland) · 2023
    Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Vladimir HolanInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic holan@biomed.cas.cz.
Peter TrosanInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Cestmir CejkaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Eliska JavorkovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Alena ZajicovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Barbora HermankovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Milada ChudickovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Jitka CejkovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Natural Science, Charles University, Prague, Czech Republic; Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic.
Czech Academy of Sciences, Institute of Experimental Medicine · CZCharles University · CZCzech Technical University in Prague · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledStem cell-based therapy has become an attractive and promising approach for the treatment of severe injuries or thus-far incurable diseases. However, the use of stem cells is often limited by a shortage of available tissue-specific stem cells; therefore, other sources of stem cells are being investigated and tested. In this respect, mesenchymal stromal/stem cells (MSCs) have proven to be a promising stem cell type. In the present study, we prepared MSCs from bone marrow (BM-MSCs) or adipose tissue (Ad-MSCs) as well as limbal epithelial stem cells (LSCs), and their growth, differentiation, and secretory properties were compared. The cells were grown on nanofiber scaffolds and transferred onto the alkali-injured eye in a rabbit model, and their therapeutic potential was characterized. We found that BM-MSCs and tissue-specific LSCs had similar therapeutic effects. Clinical characterization of the healing process, as well as the evaluation of corneal thickness, re-epithelialization, neovascularization, and the suppression of a local inflammatory reaction, were comparable in the BM-MSC- and LSC-treated eyes, but results were significantly better than in injured, untreated eyes or in eyes treated with a nanofiber scaffold alone or with a nanofiber scaffold seeded with Ad-MSCs. Taken together, the results show that BM-MSCs' therapeutic effect on healing of injured corneal surface is comparable to that of tissue-specific LSCs. We suggest that BM-MSCs can be used for ocular surface regeneration in cases when autologous LSCs are absent or difficult to obtain. SIGNIFICANCE: Damage of ocular surface represents one of the most common causes of impaired vision or even blindness. Cell therapy, based on transplantation of stem cells, is an optimal treatment. However, if limbal stem cells (LSCs) are not available, other sources of stem cells are tested. Mesenchymal stem cells (MSCs) are a convenient type of cell for stem cell therapy. The therapeutic potential of LSCs and MSCs was compared in an experimental model of corneal injury, and healing was observed following chemical injury. MSCs and tissue-specific LSCs had similar therapeutic effects. The results suggest that bone marrow-derived MSCs can be used for ocular surface regeneration in cases when autologous LSCs are absent or difficult to obtain.

Indexed as

Mesenchymal Stem Cell TransplantationAdipocytesAdipose TissueAnimalsBiomarkersBone Marrow CellsBurns, ChemicalCell- and Tissue-Based TherapyCell DifferentiationCell ProliferationEpithelial CellsEpithelium, CornealFemaleGene ExpressionLimbus CorneaeMesenchymal Stem CellsBiomarkersAlkali-injured ocular surfaceCorneal regenerationLimbal stem cellsMesenchymal stem cellsStem cell-based therapy

Identifiers

PMID26185258
PMCPMC4542873
OpenAlexW2232246899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.